Is There Room for Personalized Medicine in Small-Cell Lung Cancer (SCLC)? Remarkable Activity of Pazopanib in Refractory FGFR1-Amplified ED-SCLC.

Is There Room for Personalized Medicine in Small-Cell Lung Cancer (SCLC)? Small-cell lung cancer (SCLC) is a malignant neuroendocrine tumor that represents almost 15% of total lung cancers, characterized by distinct clinicopathologic, biologic, and therapeutic features.[1] In contrast to the impressive progress made in non-SCLC (NSCLC),[2],[3] treatment of SCLC remained relatively unchanged for more than 30 years. Preclinical data have shown in vitro and in vivo activity of the FGFR inhibitor PD173074 on SCLC growth.[15] Multiple FGFR inhibitors have been developed, and different nonselective agents have been evaluated in unselected patients with SCLC with relatively modest activity.[16],[17] To date, the role of these agents has not been evaluated in I FGFR i -amplified SCLC. In conclusion, we reported here for the first time a dramatic and sustained response to a nonselective FGFR inhibitor in a refractory, heavily pretreated ED-SCLC harboring an I FGFR1 i amplification through a plasma NGS test. FGFR1 amplification can represent a novel therapeutic target in SCLC, and clinical evaluation of novel selective FGFR inhibitors in this selected population is awaited. [Extracted from the article]